Benzinga | Nov 10, 2021 07:07AM EST

Gritstone Announces Preclinical Data In Non-Human Primate Challenge Study With Second-Generation COVID-19 Vaccine Against SARS-CoV-2

Self-amplifying mRNA (SAM) vaccination protected against SARS-CoV-2 challenge as both a 2-dose regimen and as a single boost following ChAd prime in rhesus macaques

Potential for equivalent or more potent immune responses at lower doses with SAM compared to first-generation mRNA vaccines; strong T cell responses observed

Initial Phase 1 data from Gritstone-sponsored CORAL study expected early in the first Quarter 2022